Study #2019-0171
Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients with Sarcomas
MD Anderson Study Status
Enrolling
Treatment Agent
Doxorubicin, Doxorubicin Hydrochloride, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Vincristine
Description
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delivered in the microdevice affect tumor tissue in patients with sarcomas.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Study phase:
Phase I (Early)
Physician name:
Joseph Ludwig
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.